Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
6143 results
Cited 3 times since 2011 (0.2 per year) source: EuropePMC
European journal of preventive cardiology, Volume 19, Issue 6, 19 3 2011, Pages 1316-1323 Three life years gained after reperfusion therapy in acute myocardial infarction: 25-30 years after a randomized controlled trial. Domburg RT, Hendriks JM, Kamp O, Smits P, Melle Mv, Schenkeveld L, Bax JJ, Simoons ML
Aim: Reperfusion therapy in acute myocardial infarction reduces infarct size and increases hospital survival. We investigated whether the benefit of reperfusion therapy for myocardial infarction was sustained long-term and assessed the gain in life expectancy by reperfusion therapy. Methods and results: We analysed the outcome of 533 patients (mean age 56 years, 82% men), who were randomized to either reperfusion therapy or conventional therapy during 1980-1985. Median follow up was 27 years (25... Abstract
Cited 43 times since 2011 (3.2 per year) source: EuropePMC
European journal of endocrinology, Volume 166, Issue 1, 17 3 2011, Pages 27-34 Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, Feelders RA, Bax JJ, Pereira AM
Objective: Active Cushing's syndrome (CS) is associated with cardiomyopathy, characterized by myocardial structural, and ultrastructural abnormalities. The extent of myocardial fibrosis in patients with CS has not been previously evaluated. Therefore, the objective of this study was to assess myocardial fibrosis in CS patients, its relationship with left ventricular (LV) hypertrophy and function, and its reversibility after surgical treatment. Design and methods: Fifteen consecutive CS pati... Abstract
Cited 10 times since 2011 (0.7 per year) source: EuropePMC
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, Volume 24, Issue 12, 14 2 2011, Pages 1392-1399.e1 Biventricular performance in patients with marfan syndrome without significant valvular disease: comparison to normal subjects and longitudinal follow-up. Scherptong RW, Vliegen HW, van der Wall EE, Hilhorst-Hofstee Y, Bax JJ, Scholte AJ, Delgado V
Background: The presence and progressive nature of primary myocardial involvement in Marfan syndrome are debated. The aim of this study was to evaluate the clinical relevance of left ventricular (LV) and right ventricular (RV) strain in adult patients with Marfan syndrome without significant valvular disease. Methods: Adult patients with Marfan syndrome (n = 50; mean age, 35.2 ± 12.9 years) were followed prospectively. Echocardiography was performed annually and consisted of comprehensive assess... Abstract
Cited 41 times since 2011 (3 per year) source: EuropePMC
Nature reviews. Cardiology, Volume 9, Issue 2, 11 2 2011, Pages 79-90 Restenosis after PCI. Part 2: prevention and therapy. Jukema JW, Ahmed TA, Verschuren JJ, Quax PH
The techniques and materials used during percutaneous coronary intervention have advanced considerably over the past 3 decades, yet restenosis remains one of the major drawbacks of this procedure. Many innovative technologies, including drug-eluting stents, with or without specific polymers, and fully biodegradable stents have been and continue to be developed in the search for a safe and effective antirestenosis therapy. Remarkable advances in stent design and nanoparticle delivery systems (... Abstract
Cited 27 times since 2011 (2 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 97, Issue 24, 11 2 2011, Pages 2063-2068 Intrinsic biventricular dysfunction in Marfan syndrome. de Witte P, Aalberts JJ, Radonic T, Timmermans J, Scholte AJ, Zwinderman AH, Mulder BJ, Groenink M, van den Berg MP
Background: Marfan syndrome (MFS) is an autosomal, dominantly inherited, connective tissue disorder usually caused by a mutation in the fibrillin-1 gene (FBN1). As fibrillin-1 is a component of the extracellular matrix of the myocardium, mutations in FBN1 may cause impairment of ventricular function. Furthermore, aortic elasticity is decreased in patients with MFS, which might also impair ventricular function. We assessed biventricular function and the influence of aortic elasticity in patients... Abstract
Cited 17 times since 2011 (1.3 per year) source: EuropePMC
European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, Volume 12, Issue 12, 10 2 2011, Pages 953-960 Tissue Doppler imaging in the left ventricle and right ventricle in healthy children: normal age-related peak systolic velocities, timings, and time differences. van der Hulst AE, Delgado V, Ten Harkel AD, Klitsie LM, Filippini LH, Bax JJ, Blom NA, Roest AA
Aims: Tissue Doppler imaging (TDI) enables assessment of velocities and timings within the left (LV) and the right (RV) ventricle with high temporal resolution. Knowledge on normal age-related values of peak systolic velocities and timings in healthy children may optimize the benefit of device-based therapies in paediatric patients with heart failure. Methods and results: A total of 123 healthy children (from 1 month to 18 years old) underwent TDI evaluation of the RV and LV. Peak systolic veloc... Abstract
Cited 51 times since 2011 (3.8 per year) source: EuropePMC
Circulation, Volume 124, Issue 20, 10 2 2011, Pages 2195-2201 Surgery in adults with congenital heart disease. Zomer AC, Verheugt CL, Vaartjes I, Uiterwaal CS, Langemeijer MM, Koolbergen DR, Hazekamp MG, van Melle JP, Konings TC, Bellersen L, Grobbee DE, Mulder BJ
Background: A significant proportion of patients with congenital heart disease require surgery in adulthood. We aimed to give an overview of the prevalence, distribution, and outcome of cardiovascular surgery for congenital heart disease. We specifically questioned whether the effects of surgical treatment on subsequent long-term survival depend on sex. Methods and results: From the Dutch Congenital Corvitia (CONCOR) registry for adults with congenital heart disease, we identified 10 300 patient... Abstract
Cited 2 times since 2011 (0.1 per year) source: EuropePMC
Expert opinion on investigational drugs, Volume 20, Issue 11, 7 1 2011, Pages 1517-1522 Low molecular weight heparins in the treatment of lung cancer. Mellema WW, Smit EF, Dingemans AM
Introduction: Lung cancer is the major cause of cancer-related death. Venous thromboembolic events (VTEs) occur frequently in lung cancer and are a poor prognostic marker. For prevention and treatment of VTE, low molecular weight heparins (LMWH) are superior to vitamin K antagonists. There is some evidence that LMWH may improve survival in cancer patients. Areas covered: The areas covered in this review are: lung cancer and VTEs; role of LMWH in treatment of VTEs; anticancer mechanism of heparin... Abstract
Cited 53 times since 2011 (3.9 per year) source: EuropePMC
Journal of the American College of Cardiology, Volume 58, Issue 18, 6 1 2011, Pages 1910-1918 Hemodynamic and clinical impact of prosthesis-patient mismatch after transcatheter aortic valve implantation. Ewe SH, Muratori M, Delgado V, Pepi M, Tamborini G, Fusini L, Klautz RJ, Gripari P, Bax JJ, Fusari M, Schalij MJ, Marsan NA
Objectives: This study examined the mid-term hemodynamic and clinical impact of prosthesis-patient mismatch (PPM) in patients undergoing transcatheter aortic valve implantation (TAVI) with balloon-expandable valves. Background: PPM can be observed after aortic valve surgery. However, little is known about the incidence of PPM in patients undergoing TAVI. Methods: Echocardiography and clinical assessment were performed in 165 patients at baseline, before hospital discharge, and at 6 months after... Abstract
Cited 27 times since 2011 (2 per year) source: EuropePMC
BMC medical genetics, Volume 12, 6 1 2011, Pages 131 Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. Trompet S, de Craen AJ, Postmus I, Ford I, Sattar N, Caslake M, Stott DJ, Buckley BM, Sacks F, Devlin JJ, Slagboom PE, Westendorp RG, Jukema JW, PROSPER Study Group
Background: The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide association study in the PROspective Study of Pravastatin in the Elderly at risk for vascular disease (PROSPER) that investigates the genetic variation responsible for the individual variation in drug response to pravastatin. Statins lower LDL-cholesterol in general by 30%, however not in all subjects. Moreover, clinical response is highly variable and adverse effects occur in a minority of patients.... Abstract
Cited 28 times since 2011 (2.1 per year) source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Volume 14, Issue 4, 4 1 2011, Pages 522-527 Long-term outcome of ablative therapy of post-operative atrial tachyarrhythmias in patients with tetralogy of Fallot: a European multi-centre study. de Groot NM, Lukac P, Schalij MJ, Makowski K, Szili-Torok T, Jordaens L, Nielsen JC, Jensen HK, Gerdes JC, Delacretaz E
Aim: Post-operative atrial tachyarrhythmias (AT) in patients with tetralogy of Fallot (ToF) are associated with congestive heart failure, stroke, and cardiac death. Effective treatment is therefore essential. The aim of the study is to evaluate long-term outcome of ablative therapy of AT in ToF patients and to study characteristics of AT recurrences. Methods and results: Tetralogy of Fallot patients (N = 38, age 43 ± 12 years) referred for ablation of post-operative AT, appearing 26 ± 10 years a... Abstract
Cited 1 times since 2011 (0.1 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 19, Issue 10, 1 1 2011, Pages 440-441 Paroxysmal mechanical aortic valve prosthesis dysfunction: capturing the right moment. Sorgdrager BJ, Tavilla G, van der Wall EE, Scholte AJ
Cited 1 times since 2011 (0.1 per year) source: EuropePMC
Current pharmaceutical design, Volume 17, Issue 30, 1 1 2011, Pages 3308-3327 Cell therapy for the treatment of chronic ischemic heart disease. Rodrigo SF, Ramshorst Jv, Beeres SL, Bax JJ, Schalij MJ, Atsma DE
Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patients with chronic ischemic heart disease. After initial clinical studies have provided evidence for safety of cell administration, larger randomized trials demonstrated variable effect... Abstract
Cited 5 times since 2011 (0.4 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 19, Issue 10, 1 1 2011, Pages 432-435 Per-operative stent placement in the right pulmonary artery; a hybrid technique for the management of pulmonary artery branch stenosis at the time of pulmonary valve replacement in adult Fallot patients. Windhausen F, Boekholdt SM, Bouma BJ, Groenink M, Backx AP, de Winter RJ, Mulder BJ, Hazekamp MG, Koolbergen DR
After having undergone surgical correction at an early age, many patients with tetralogy of Fallot develop long-term complications including progressive pulmonary regurgitation and peripheral pulmonary stenosis. A high percentage of these patients need to undergo a second operation in their adolescence or early adulthood. If simultaneous treatment of both pulmonary regurgitation and peripheral pulmonary stenosis is warranted, a complete surgical approach has several disadvantages. We describe fo... Abstract
The international journal of cardiovascular imaging, Volume 27, Issue 7, 1 1 2011, Pages 989-993 CMR-determined scar volume: predictive for ventricular tachycardias? van der Wall EE, Zeppenfeld K, Bax JJ, Siebelink HM, Schalij MJ
Cited 15 times since 2011 (1.1 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 97, Issue 20, 1 1 2011, Pages 1704-1714 Multimodality imaging before, during, and after percutaneous mitral valve repair. Delgado V, Kapadia S, Marsan NA, Schalij MJ, Tuzcu EM, Bax JJ
Cited 21 times since 2011 (1.6 per year) source: EuropePMC
Archives of orthopaedic and trauma surgery, Volume 132, Issue 2, 30 5 2011, Pages 257-263 Determinants of outcome in operatively and non-operatively treated Weber-B ankle fractures. Van Schie-Van der Weert EM, Van Lieshout EM, De Vries MR, Van der Elst M, Schepers T
Introduction: Treatment of ankle fractures is often based on fracture type and surgeon's individual judgment. Literature concerning the treatment options and outcome are dated and frequently contradicting. The aim of this study was to determine the clinical and functional outcome after AO-Weber B-type ankle fractures in operatively and conservatively treated patients and to determine which factors influenced outcome. Patients and methods: A retrospective cohort study in patients with a AO-W... Abstract
Cited 49 times since 2011 (3.6 per year) source: EuropePMC
Ageing research reviews, Volume 11, Issue 1, 29 5 2011, Pages 67-77 A systematic review of 'knowledge of dementia' outcome measures. Spector A, Orrell M, Schepers A, Shanahan N
Knowledge of dementia measures are key to identifying areas of misinformation and establishing knowledge levels, thus guiding educational programmes and interventions. A three-step literature search was undertaken to identify measures of knowledge in dementia. An evaluation framework was employed articulating quality indicators for the psychometric properties of measures, based on their development and use within research studies. Five measures were identified: the Alzheimer's Disease Knowl... Abstract
Cited 27 times since 2011 (2 per year) source: EuropePMC
American journal of physiology. Lung cellular and molecular physiology, Volume 302, Issue 1, 23 4 2011, Pages L56-67 Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. de Visser YP, Walther FJ, Walther FJ, Laghmani el H, Steendijk P, Middeldorp M, van der Laarse A, Wagenaar GT
Phosphodiesterase (PDE) 4 inhibitors are potent anti-inflammatory drugs with antihypertensive properties, and their therapeutic role in bronchopulmonary dysplasia (BPD) is still controversial. We studied the role of PDE4 inhibition with piclamilast on normal lung development and its therapeutic value on pulmonary hypertension (PH) and right ventricular hypertrophy (RVH) in neonatal rats with hyperoxia-induced lung injury, a valuable model for premature infants with severe BPD. The cardiopulmonar... Abstract
Cited 2 times since 2011 (0.1 per year) source: EuropePMC
Revista espanola de cardiologia, Volume 64, Issue 11, 22 4 2011, Pages 1035-1044 [Three-dimensional imaging in cardiac resynchronization therapy]. Auger D, Schalij MJ, Bax JJ, Delgado V
Cardiac resynchronization therapy improves clinical symptoms and prognosis of heart failure patients. However, it has been shown that up to 40% of patients do not respond to this therapy. Three main determinants of cardiac resynchronization therapy response have been identified: left ventricular dyssynchrony, left ventricular lead position, and extent and location of myocardial scar tissue. Two-dimensional echocardiography is the first imaging technique to evaluate patients who may be candidates... Abstract